^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
SHR-1916
i
Other names: SHR-1916
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hengrui Pharma
Drug class:
IL-2 stimulant
Related drugs:
3ms
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=11, Terminated, Jiangsu HengRui Medicine Co., Ltd. | N=50 --> 11 | Recruiting --> Terminated; R&d strategy adjustment
Enrollment change • Trial termination • Metastases
|
SHR-1916
3years
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=50, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
CD8 (cluster of differentiation 8)
|
SHR-1916
3years
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
Clinical • New P1 trial
|
CD8 (cluster of differentiation 8)
|
SHR-1916
Share via
